00:03 , Aug 23, 2019 |  BC Innovations  |  Distillery Therapeutics

KRAS inhibitor combinations for improved therapeutic efficacy

DISEASE CATEGORY: Cancer INDICATION: Lung cancer, pancreatic cancer UCSF’s Kevan Shokat and colleagues have identified two sets of genes for which inhibition could improve the efficacy of KRAS G12C inhibitors. Through a CRISPR-based screen in...
12:00 , Aug 22, 2019 |  BC Extra  |  Financial News

Eyeing new endpoints, Versant-backed Chinook reels in $65M series A for kidney therapies

Increased momentum in the kidney disease space, sparked in part by an evolution in FDA's thinking about approvable endpoints, encouraged a VC syndicate to back newly launched Chinook with $65 million in series A funding....
20:25 , Aug 21, 2019 |  BC Innovations  |  Distillery Therapeutics

Targeting CAD or DHODH to inhibit pyrimidine synthesis for glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Blocking pyrimidine synthesis via inhibition of CAD or DHODH, an enzyme downstream CAD, could treat glioblastoma. In patients, high tumor expression of a pyrimidine metabolism gene signature was associated...
17:51 , Aug 21, 2019 |  BC Extra  |  Clinical News

AZ's Imfinzi/tremelimumab combo misses again, this time in another NSCLC

AstraZeneca announced Wednesday that its Imfinzi durvalumab/tremelimumab combination failed to show a survival benefit in first-line non-small cell lung cancer. While the miss marks an end to AZ's recent spate of clinical successes, investors appeared...
21:38 , Aug 15, 2019 |  BC Innovations  |  Distillery Therapeutics

Melding bispecifics and CAR T cells to treat glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer An anti-EGFRvIII CAR T cell engineered to secrete an anti-CD3, anti-EGFR bispecific antibody could treat glioblastoma. In a mouse model of EGFRvIII-positive or EGFRvIII-negative glioblastoma, the engineered cells decreased...
20:13 , Aug 15, 2019 |  BC Innovations  |  Translation in Brief

Marrying CARs and bispecifics for solid tumors

Companies are split on whether CAR T cells or bispecifics will be most efficacious in solid tumors, but one group thinks the best bet is to combine the approaches. A Harvard Medical School team unveiled...
23:48 , Aug 13, 2019 |  BC Extra  |  Company News

Aug. 13 Company Quick Takes: Pharming licenses Novartis' CDZ173; plus Novartis, Merck-Harvard, Mustang, J&J

Pharming licenses Novartis autoimmune candidate  Pharming Group N.V. (Euronext:PHARM) gained rights to PI3Kδ inhibitor CDZ173 from Novartis AG (NYSE:NVS; SIX:NOVN) for patients with activated PI3Kδ syndrome, a primary immune deficiency. Novartis will receive $20 million...
02:02 , Aug 10, 2019 |  BioCentury  |  Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

The rush to drug CD47 shows no signs of abating, with five companies launching clinical programs for cancer this year and three moving forward on the back of encouraging Phase I data. The differentiator may...
21:35 , Aug 9, 2019 |  BC Extra  |  Clinical News

Aug. 9 Clinical Quick Takes: Lexicon's one-year Zynquista follow-up; plus 89bio and TopiVert

Biomarker data lift Lexicon   Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) rose $0.25 (20%) to $1.53 Friday after reporting pooled 52-week follow-up data from two Phase III trials showing that Zynquista sotagliflozin lowered biomarker levels of chronic...
18:56 , Aug 9, 2019 |  BC Extra  |  Clinical News

AZ notches another win in cancer with Tagrisso in NSCLC

AstraZeneca continued its momentum of positive cancer news this summer as Tagrisso osimertinib showed a survival benefit in first-line NSCLC. AstraZeneca plc (LSE:AZN; NYSE:AZN) said the oral irreversible inhibitor of EGFR activating mutations significantly improved...